EnsoData announced the closing of a $20 million Series A extension, led by Inspire Medical Systems, Inc. (NYSE: INSP), with participation from existing investors including Zetta Venture Partners, Venture Investors, Supermoon Capital, Colle Capital, HealthX Ventures, M25 Ventures, Board members Justin Mortara, Ph.D., ‹‹Fred Robertson, MD, and other investors.

EnsoData provides artificial intelligence based software-as-a-service that automates complex, arduous, and time-consuming data analysis for frontline clinicians. Their first product, EnsoSleep, is FDA cleared to automate the scoring of in-lab and home sleep studies and aid clinicians in the diagnosis of sleep disorders like sleep apnea.